PDF⋙ Progestogens for Prevention of Preterm Birth: Comparative Effectiveness Review Number 74 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality
Progestogens for Prevention of Preterm Birth: Comparative Effectiveness Review Number 74 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality
Progestogens for Prevention of Preterm Birth: Comparative Effectiveness Review Number 74 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality PDF, ePub eBook D0wnl0ad
Birth before completion of 37 weeks of pregnancy is considered preterm. These early births are associated with more than 85 % of all perinatal morbidity and mortality and are the leading cause of infant mortality and long-term disability. Each year in the U.S. more than 475,000 infants are born preterm representing 12.5 % of live births. Efforts to reduce preterm birth have been largely unsuccessful, with a 20 % relative increase since 1990 in the proportion of births in the U.S. that are preterm. Morbidity and mortality associated with preterm birth represent untold distress for families, as well as significant costs to patients, health care systems, and payers. Average neonatal care costs are estimated to be $17,300 greater for preterm infants relative to term infants, amounting to more than $8.6 billion of annual medical spending in the U.S. The ultimate goal in preventing preterm birth is to eliminate the risks of neonatal complications and death and to ensure normal development. In the last decade, accumulating evidence from randomized clinical trials (RCTs) has led professional organizations and an Institute of Medicine working group to endorse the use of progestogens for women with prior spontaneous preterm birth. However, these groups also note interest in assessing long-term safety because the legacy of diethylstilbestrol suggests caution and extended followup of mothers and infants after hormone use in pregnancy. Unresolved issues about choice of progestogen, optimal route of drug delivery, and other candidate high-risk populations for treatment remain. To review the current state of the evidence we answered the following Key Questions. 1. In pregnant women who are at risk for preterm birth (which is birth before 37 weeks gestational age), does progestogen treatment, compared to a placebo, usual care, or other interventions improve maternal or fetal/neonatal health outcomes, including but not limited to: Complications during pregnancy (e.g., chorioamnionitis, antenatal hospitalizations and intrauterine growth restriction)? Mode of birth and complications during birth (e.g., cesarean birth and surgical complications)? Prematurity? Postpartum and neonatal complications (e.g., maternal postpartum hemorrhage and intraventricular hemorrhage)? Longer term outcomes (e.g., neurodevelopmental delay and future reproductive outcomes)? 2. What is the nature and frequency of maternal and child adverse effects of progestogen treatment, including but not limited to: Complications during pregnancy (e.g. allergic reactions or development of gestational diabetes)? Mode of birth and complications during birth (e.g., unanticipated maternal harms)? Postpartum and neonatal complications (e.g., infections and sepsis)? Longer term outcomes? 3. How do the effectiveness, adverse effects, and safety of progestogen treatment differ based on the maternal risk factors for preterm birth, such as severity of prior preterm birth, degree of cervical shortening, order of multiple gestations, fetal fibronectin status, preterm premature rupture of membranes (PPROM), threatened preterm birth, and socioeconomic predictors of prematurity, including race/ethnicity? 4. How do the effectiveness, acceptability, adherence, adverse effects, and safety of progestogen treatment differ, based on the formulation, dose, frequency of administration, and gestational age at initiation or discontinuation of progestogen therapy? 5. How do the effectiveness, adverse effects, and safety of progestogen treatment differ based on cointerventions used to prevent preterm birth and its consequences, including antibiotics, corticosteroids, tocolysis, and surgical interventions such as cervical cerclage? 6. What are the effects of health system and provider factors, including provider knowledge and attitudes, provider specialty, cost of drug, availability of drug in formularies, and Medicaid and private payer coverage, on the utilization of progestogens for eligible at risk women?From reader reviews:
Mildred Olsen:
Reading a guide tends to be new life style in this particular era globalization. With studying you can get a lot of information which will give you benefit in your life. Along with book everyone in this world can easily share their idea. Books can also inspire a lot of people. A lot of author can inspire their particular reader with their story or even their experience. Not only the story that share in the ebooks. But also they write about the ability about something that you need example. How to get the good score toefl, or how to teach your children, there are many kinds of book that you can get now. The authors on this planet always try to improve their skill in writing, they also doing some research before they write for their book. One of them is this Progestogens for Prevention of Preterm Birth: Comparative Effectiveness Review Number 74.
Bernice Martinez:
This Progestogens for Prevention of Preterm Birth: Comparative Effectiveness Review Number 74 is great book for you because the content that is certainly full of information for you who else always deal with world and have to make decision every minute. This book reveal it facts accurately using great plan word or we can say no rambling sentences in it. So if you are read this hurriedly you can have whole information in it. Doesn't mean it only provides straight forward sentences but tricky core information with wonderful delivering sentences. Having Progestogens for Prevention of Preterm Birth: Comparative Effectiveness Review Number 74 in your hand like getting the world in your arm, data in it is not ridiculous one particular. We can say that no publication that offer you world inside ten or fifteen second right but this book already do that. So , it is good reading book. Hey there Mr. and Mrs. active do you still doubt that will?
Nicole Floyd:
Many people said that they feel bored stiff when they reading a book. They are directly felt it when they get a half regions of the book. You can choose typically the book Progestogens for Prevention of Preterm Birth: Comparative Effectiveness Review Number 74 to make your own personal reading is interesting. Your personal skill of reading proficiency is developing when you just like reading. Try to choose very simple book to make you enjoy to learn it and mingle the sensation about book and reading through especially. It is to be 1st opinion for you to like to start a book and study it. Beside that the book Progestogens for Prevention of Preterm Birth: Comparative Effectiveness Review Number 74 can to be a newly purchased friend when you're really feel alone and confuse with what must you're doing of the time.
Read Progestogens for Prevention of Preterm Birth: Comparative Effectiveness Review Number 74 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality for online ebook
Progestogens for Prevention of Preterm Birth: Comparative Effectiveness Review Number 74 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality Free PDF d0wnl0ad, audio books, books to read, good books to read, cheap books, good books, online books, books online, book reviews epub, read books online, books to read online, online library, greatbooks to read, PDF best books to read, top books to read Progestogens for Prevention of Preterm Birth: Comparative Effectiveness Review Number 74 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality books to read online.
Komentar
Posting Komentar